Keith Kerr, BSc, MB, ChB, consultant pathologist, University of Aberdeen, Aberdeen, Scotland, discusses common misconceptions with molecular profiling in lung cancer.
Keith Kerr, BSc, MB ChB
Advertisement
Articles by Keith Kerr, BSc, MB ChB
Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.
Advertisement
Latest Updated Articles
Dr. Keith Kerr on Selecting Patients for Immunotherapy in Lung CancerPublished: July 6th 2016 | Updated:
Dr. Kerr on Misconceptions With Molecular Profiling in Lung CancerPublished: October 16th 2018 | Updated:
Dr. Keith Keer on PD-L1 in Lung CancerPublished: May 26th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5